Mirati Therapeutics Reports Promising Data from Clinical Trials

Mirati Therapeutics Reports Promising Data from Clinical Trials

Mirati Therapeutics reported late Thursday promising data from two ongoing clinical programs, including the Phase 1b and Phase 2 trials of glesatinib, a spectrum selective kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET, and the Phase 1b trial of sitravatinib, a receptor tyrosine kinase inhibitor for the treatment of genetically-selected NSCLC and other solid tumors. Shares were down 6% in the […]

Read More ˃
Interface to Close Most FLOR Stores in Restructuring Plan

Interface to Close Most FLOR Stores in Restructuring Plan

Interface will close the majority of its FLOR retail stores between January and April and take a charge of a total of about $25 to $27 million in a restructuring plan. The job reductions include about 70 FLOR workers and “a number of other employees in the commercial business in the Americas and Europe regions,” the company said. In Q4 2016, the company expects to incur a pre-tax restructuring and […]

Read More ˃